Among the serous gene set, OncoPrint results showed the following 26 genes were amplified in more than 5% of HGSO adenocarcinoma patient samples: ATPase family AAA domain containing 2 (ATAD2), recQ-like helicase 4 (RECQL4), LY6E, MECOM, GPR160, cyclin E1 (CCNE1), ECT2, LAMP3, ECE2, PLAAT1, anti-silencing function 1B histone chaperone (ASF1B), MUC16, BCAT1, LSR, CTHRC1, ribonuclease H2 subunit A (RNASEH2A), PRSS2, GRHL2, NR2F6, structural maintenance of chromosomes 4 (SMC4), SLC2A1, cell division cycle associated 20 (CDC20), S100A2, SCNN1A, cell division cycle associated 8 (CDCA8), and FOXM1. This evidence concerns the gene SLC2A1 and adenocarcinoma.